Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Milan – page 153

2 423 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Milan at a glance
2 423
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 423 trials in Milan

Open in trial search

Acute graft versus host disease

Not recruiting

Study on the Effectiveness and Safety of CYP-001 and Corticosteroids for Adults with High-Risk Acute Graft Versus Host Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Mesenchymoangioblast-Derived Mesenchymal Stem Cells
  • Sponsor:Cynata Therapeutics Limited

Prodromal Alzheimer's disease

Not recruiting

Study of RO7269162 in people at risk for or with early-stage Alzheimer's Disease: Effects on brain amyloid buildup

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Pulmonary arterial hypertension

Not recruiting

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Hormone-refractory prostate cancer

Not recruiting

Study of Olaparib and Abiraterone for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:AstraZeneca AB

Progressive supranuclear palsy

Not recruiting

Study on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Phenylbutyrate
  • Sponsor:Amylyx Pharmaceuticals Inc.

HER2 positive breast cancer

Not recruiting

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Glioblastoma

Not recruiting

Study on the Safety and Effectiveness of 2-Hydroxyoleic Acid and Temozolomide with Radiotherapy for Patients with Newly Diagnosed Glioblastoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Idroxioleic acid
  • Sponsor:Laminar Pharmaceuticals S.A.

Study of Glofitamab, Atezolizumab, and Polatuzumab Vedotin for Adults with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Ovarian cancer

Not recruiting

Study of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Milan

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.

  • Metastatic Colorectal Cancer Treatment
  • Breast Cancer Prevention Strategies
  • Advanced Solid Malignancies

Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.

02 Neurological Disorders

Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.

  • Frontotemporal Dementia
  • Parkinson's Disease
  • Migraine Treatment

Focus on developing targeted therapies and understanding disease mechanisms.

03 Immunology and Infectious Diseases

Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.

  • Immune Thrombocytopenia
  • RSV Prevention
  • HIV Prevention

Emphasis on developing novel preventive strategies and therapeutic solutions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.